CDK12 INHIBITION REVERSES DE NOVO AND ACQUIRED PARP INHIBITOR RESISTANCE IN BRCA WILD-TYPE AND MUTATED MODELS OF TRIPLE-NEGATIVE BREAST CANCER

Although poly (ADP-ribose) polymerase (PARP) inhibitors are active in homologous recombination (HR)-deficient cancers, their utility is limited by acquired resistance following restoration of HR. Here, we report that dinaciclib, an inhibitor of cyclin-dependent kinases (CDKs) 1, 2, 5 and 9, addition...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cell Rep
Autori principali: Johnson, Shawn F., Cruz, Cristina, Greifenberg, Ann Katrin, Dust, Sofia, Stover, Daniel G., Chi, David, Primack, Benjamin, Cao, Shiliang, Bernhardy, Andrea J., Coulson, Rhiannon, Lazaro, Jean-Bernard, Kachupurakkal, Bose, Sun, Heather, Unitt, Christine, Moreau, Lisa A., Sarosiek, Kristopher A., Scaltriti, Maurizio, Juric, Dejan, Baselga, José, Richardson, Andrea L., Rodig, Scott J., D’Andrea, Alan D., Balmaña, Judith, Johnson, Neil, Geyer, Matthias, Serra, Violeta, Lim, Elgene, Shapiro, Geoffrey I.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5176643/
https://ncbi.nlm.nih.gov/pubmed/27880910
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2016.10.077
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi